Methods of diagnosis of ovarian cancer, compositions and methods of screening for modulators of ovarian cancer
View Patent ↗Described herein are genes whose expression are up-regulated or down-regulated in ovarian cancer. Related methods and compositions that can be used for diagnosis and treatment of ovarian cancer are disclosed. Also described herein are methods that can be used to identify modulators of ovarian cancer.
1. A method of detecting ovarian cancer in a patient, the method comprising:
(i) detecting a nucleic acid in a first sample from the patient, wherein the nucleic acid is at least 95% identical to a sequence selected from the group consisting of SEQ ID NOs: 13, 15, 17, 19 and 21, and wherein the nucleic acid encodes a G protein-coupled receptor 64; and
(ii) comparing the expression level of the nucleic acid in the first sample to the expression level in a normal sample,
wherein an increase in the level of the nucleic acid relative to a normal sample is indicative of ovarian cancer.
2. The method of claim 1 , wherein the first sample comprises isolated nucleic acids.
3. The method of claim 2 , wherein the nucleic acids are mRNA.
4. The method of claim 2 , further comprising the step of amplifying nucleic acids before the step of detecting the nucleic acid.
5. The method of claim 1 , wherein the detecting step is carried out by using a nucleic acid probe that hybridizes under stringent conditions to SEQ ID NO: 21.
6. The method of claim 1 , wherein the probe is immobilized on a solid surface.
7. The method of claim 1 , wherein the patient is undergoing a therapeutic regimen to treat ovarian cancer.
8. The method of claim 1 , wherein the patient is suspected of having ovarian cancer.
9. The method of claim 1 wherein the nucleic acid comprises a sequence selected from the group consisting of SEQ ID NOs: 13, 15, 17, 19 and 21.
10. A method of monitoring ovarian cancer in a human patient, the method comprising:
(i) detecting a nucleic acid in a first sample from the patient, wherein the nucleic acid is at least 95% identical to a sequence selected from the group consisting of SEQ ID NOs: 13, 15, 17, 19 and 21, and wherein the nucleic acid encodes a G protein-coupled receptor 64;
(ii) comparing the expression level of the nucleic acid in the first sample to the expression level in a normal sample.
11. The method of claim 10 , wherein the sample comprises blood from the patient.
12. The method of claim 10 , wherein the nucleic acid comprises a sequence selected from the group consisting of SEQ ID NOs: 13, 15, 17, 19 and 21.
13. The method of claim 10 , wherein the detecting step is carried out by using a nucleic acid probe that hybridizes under stringent conditions to a sequence at least 95% identical to a sequence selected from the group consisting of SEQ ID NOs: 13, 15, 17, 19 and 21.